Goal Oriented Strategy to Preserve Ejection Fraction Trial

• Status: Unknown status
• Trial end date: 2017-09-01
• Target enrollment: 0
• Participant gender: All

Summary

In this prospective long term feasibility study we examine whether a goal oriented therapeutic strategy that is able to preserve right ventricular function will result in improved clinical outcome in patients with pulmonary arterial hypertension. We hypothesize that right ventricular function can only be preserved when early and aggressive medical combination therapy not only reduces pulmonary vascular resistance but also pulmonary pressures.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: VU University Medical Center
• Treatments: Bosentan; Macitentan; Sildenafil Citrate; Tadalafil

Criteria

Inclusion Criteria:

• Idiopathic or heritable pulmonary arterial hypertension

• New York Heart Association (NYHA) functional class II or III

Exclusion Criteria:

• Other causes of pulmonary arterial hypertension (i.e. collagen vascular disease, congenital heart disease, chrono-thromboembolic pulmonary hypertension, pulmonary venous hypertension, left heart failure, hypoxemic lung disease)

• Pulmonary arterial hypertension targeted therapies before study inclusion